At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
sirolimusdrug
Likely dose
sirolimus 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical, Biological and Pharmacological Study of Rapamycin (Rapamune®, Sirolimus) in Patients With Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jul 11, 2007·Updated Oct 19, 2016
In Brief
A Phase 2 clinical trial evaluating sirolimus for Pancreatic Cancer. Completed, enrolled 47 participants across 1 site.
Detailed Summary
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well sirolimus works in treating patients with advanced pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedJul 2007
Primary CompletionSep 2008
Study CompletionJun 2009
TodayJul 2026
First PostedJul 11, 2007
Enrollment StartJan 1, 2005
Primary CompletionSep 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.0 years ago
Interventions
sirolimusdrug
Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.